

AMERICAN VIETNAMESE

BIOTECH INC

Number: 50/2026/CV - AMV

Subject: Disclosure of Financial Statements
for Q3/2026 and

Explanation of profit discrepancies

SOCIALIST REPUBLIC OF VIETNAM

Independence - Freedom - Happiness

Ho Chi Minh City, October 30, 2026

**Dear: - STATE SECURITIES COMMISSION;
- HANOI STOCK EXCHANGE.**

Company Name : **AMERICAN VIETNAMESE BIOTECH INC**

Stock ticker: **AMV**

Head office address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai Street, Tan My Ward,
Ho Chi Minh City, Vietnam

Phone: Fax:

Information released by: **Dang Nhi Nuong**

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai Street, Tan My Ward, Ho Chi
Minh City, Vietnam.

Telephone (mobile, office, home):

Type of information to be released: ☐ 24-hour ☐ irregular ☐ information as requested ☒
periodically

Content of published information (*):

In accordance with Circular No. 96/2020/TT-BTC dated November 16, 2020, of the Ministry of
Finance, AMERICAN VIETNAMESE BIOTECH INC hereby reports to the Committee and the
Department on the disclosure of the Financial Report for the third quarter of 2026 as follows:

I. Separate financial statements

1. Explanation of the change in after-tax profit in the Statement of Income for the reporting period
of 10% or more compared to the same period of the previous year, shifting from profit in the
same period of the previous year to loss in this period, is as follows:

- Business results for the third quarter of 2025
Revenue: 3,130,895,606 VND
Cost of goods sold : 3,922,523,425 VND
+ Net profit after tax: (9,254,244,063) VND
- Business results for the third quarter of 2026
+ Revenue: 19,179,406,592 VND
+ Cost of goods sold 19,799,834,250 VND
+ Net profit after tax: (15,662,802,016) VND

2. Explanation of the reasons

The after-tax profit on the parent company's Q3 2026 financial statement was VND
15,662,802,016. The main reason is the increase in provisions for financial investments
compared to the same period last year.



II. Consolidated financial statements

1. Explanation of the change in after-tax profit in the Statement of Income for the reporting period of 10% or more compared to the same period of the previous year, shifting from profit in the same period of the previous year to loss in this period, is as follows:

- Business results for the third quarter of 2025
 - + Revenue: 12,690,778,785 VND
 - Cost of goods sold: 7,953,554,744 VND
 - + Net profit after tax: (10,861,433,350) VND
- Business results for the third quarter of 2026
 - + Revenue: 27,658,250,823 VND
 - Cost of goods sold: 29,701,281,599 VND
 - + Net profit after tax: (22,405,077,717) VND

2. Explanation of the reasons

The after-tax profit on the Company's Consolidated Financial Statements for the third quarter of 2026 was VND 22,405,077,717. The main reason is the increase in provisions for financial investments compared to the same period last year.

III. The above information was posted on our company's website on October 30, 2026 at the following address:

<https://amvibiotech.com/category/bao-cai-tai-chinh/>

AMERICAN VIETNAMESE BIOTECH INC commits that the information provided above is truthful and accurate.

Thank you very much!

Recipient:

- As above.
- Save VP.

**ĐẶNG NHỊ
NƯƠNG**

Digitally signed by ĐẶNG NHỊ NƯƠNG
DN: C=VN, S=HỒ CHÍ MINH, L=Quận 7, O=
CÔNG TY CỔ PHẦN SẢN XUẤT KINH DOANH
DƯỢC VÀ TRANG THIẾT BỊ Y TẾ VIỆT MỸ,
OU=Giám đốc, T=Giám đốc, CN=ĐẶNG NHỊ
NƯƠNG, OID.0.9.2342.19200300.100.1.1=
CCCD:001156020169
Reason: I am the author of this document
Location:
Date: 2026.10.30 17:03:36+07'00'
Foxit PDF Reader Version: 12.1.3

AMERICAN VIETNAMESE BIOTECH INC



GIÁM ĐỐC
Đặng Nhị Nương

